COVAX Facility

Gavi is co-leading COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator. This involves coordinating the COVAX Facility, a global risk-sharing mechanism for pooled procurement and equitable distribution of eventual COVID-19 vaccines.

Learn more

Top stories

View all news

Memorandum of understanding signed today will strengthen collaboration on vaccination efforts and related health services for migrants and forcibly displaced persons across the world

Geneva, 24 November 2020 – Gavi, the Vaccine Alliance, as co-lead of COVAX and administrator of the COVAX Facility, welcomes the release of interim efficacy data for the AstraZeneca/Oxford COVID-19 vaccine candidate.

The COVAX AMC Engagement Group, composed of Gavi COVAX AMC participants, donors, and other stakeholders, forms a key component of Facility governance.

The COVID-19 vaccine race

Pre-clinical
154vaccines
are being explored in lab experiments and animals
PHASE 1
21 vaccines
are undergoing safety tests in healthy young individuals
Phase 2
13vaccines
are being tested in broader groups of people
Phase 3
10vaccines
are in large international trials to test their impact on COVID-19
APPROVED
0vaccines
are approved and licensed for general use

Learn more

#VaccinesWork

Vaccines are one of the most successful and cost-effective health investments in history with wider benefits that accrue across a lifetime.

Keep informed about the latest topics in global health, including top stories related to the ongoing coronavirus (COVID-19) outbreak.

Learn more

Vaccines are one of the most successful and cost-effective health investments in history with wider benefits that accrue across a lifetime.

Keep informed about the latest topics in global health, including top stories related to the ongoing coronavirus (COVID-19) outbreak.

Learn more

Top VaccinesWork stories

View all stories

Janet, mother of twins, tells fellow mothers.

Most vaccines are given to healthy people to prevent infection with a disease-causing organism, but sometimes vaccines are used to fight an existing infection or illness. Such ‘therapeutic’ vaccines are being developed for numerous illnesses,…

Scientists around the world are working faster than ever to find vaccines that could stop the spread of COVID-19. Now, nearly a year on from the start of the pandemic, we have several promising vaccines on the brink of going through regulatory…

Supported countries

Supported Countries

Our impact

Syringe >822 million children immunised
First aid locator >14 million future deaths prevented
Transitioned 16 countries transitioned from Gavi support
Billions >150 US$ billion in economic benefits for countries
Children 85% of the world's children reached by routine immunisation

Our mission: protect people's health

Saving children’s lives and protecting people’s health by increasing equitable use of vaccines in lower-income countries

Learn more

Saving children’s lives and protecting people’s health by increasing equitable use of vaccines in lower-income countries

Learn more

Our partners

Gavi draws on the skills of a variety of partners, combining the technical expertise of the development community with the business know-how of the private sector.

Meet the Vaccine Alliance partners

Gavi draws on the skills of a variety of partners, combining the technical expertise of the development community with the business know-how of the private sector.

Meet the Vaccine Alliance partners

Like. Follow. Share.

    Subscribe to our newsletter